Watchlist Price Alert

Day One Biopharmaceutical... (DAWN)

NASDAQ: DAWN · Real-Time Price · USD

6.67

-0.02 (-0.30%)

At close: Jun 13, 2025, 3:59 PM

6.79

1.88%

After-hours: Jun 13, 2025, 04:48 PM EDT

-0.30% (1D)

Bid	6.5
Market Cap	675.58M
Revenue (ttm)	161.92M
Net Income (ttm)	-69.08M
EPS (ttm)	-0.65
PE Ratio (ttm)	-10.25
Forward PE	-7.97
Analyst	Buy

Ask	6.8
Volume	1,010,178
Avg. Volume (20D)	1,272,182
Open	6.57
Previous Close	6.69
Day's Range	6.53 - 6.75
52-Week Range	6.08 - 16.76
Beta	-1.30

About DAWN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DAWN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DAWN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

-16.5%

Day One Biopharmaceuticals shares are trading lowe... Unlock content with Pro Subscription

7 months ago

+0.84%

Day One Biopharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

News

1 week ago · seekingalpha.com

Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

DAWN reported modest Q1'25 sales growth vs Q4'24, and the reaction of the stock has unsurprisingly been muted. Upcoming Q2'25 earnings are pivotal: confirmation of accelerating growth could spark upsi...

1 month ago · seekingalpha.com

Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy B...

1 month ago · zacks.com

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.72 per share a year ago.

2 months ago · https://www.marketscreener.com

Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment

The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...

2 months ago · seekingalpha.com

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

Day One Biopharmaceuticals' Ojemda launched in Q2'24 and generated $57.2M in net product revenues in 2024. Despite reporting continued sales growth so far, DAWN's stock is near 52-week lows, perhaps i...